Overview

A Phase II Study to Evaluate HLX43 in Subjects with Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-22
Target enrollment:
Participant gender:
Summary
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Henlius Biotech